Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study

C. Onal, Y. X. Li, R. C. Miller, P. Poortmans, N. Constantinou, D. C. Weber, B. M. Atasoy, S. Igdem, M. Ozsahin, E. Ozyar

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalAnnals of Oncology
Volume22
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Lymphoma
Thyroid Gland
Disease-Free Survival
Neoplasms
Survival
Therapeutics
Survival Rate
Lymph Nodes
Thyroiditis
Radiotherapy
Multivariate Analysis
Drug Therapy

Keywords

  • Chemotherapy
  • Combined modality treatment
  • Non-Hodgkin's lymphoma
  • Prognostic factors
  • Radiotherapy
  • Thyroid lymphoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Onal, C., Li, Y. X., Miller, R. C., Poortmans, P., Constantinou, N., Weber, D. C., ... Ozyar, E. (2011). Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study. Annals of Oncology, 22(1), 156-164. https://doi.org/10.1093/annonc/mdq310

Treatment results and prognostic factors in primary thyroid lymphoma patients : A Rare Cancer Network study. / Onal, C.; Li, Y. X.; Miller, R. C.; Poortmans, P.; Constantinou, N.; Weber, D. C.; Atasoy, B. M.; Igdem, S.; Ozsahin, M.; Ozyar, E.

In: Annals of Oncology, Vol. 22, No. 1, 2011, p. 156-164.

Research output: Contribution to journalArticle

Onal, C, Li, YX, Miller, RC, Poortmans, P, Constantinou, N, Weber, DC, Atasoy, BM, Igdem, S, Ozsahin, M & Ozyar, E 2011, 'Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study', Annals of Oncology, vol. 22, no. 1, pp. 156-164. https://doi.org/10.1093/annonc/mdq310
Onal, C. ; Li, Y. X. ; Miller, R. C. ; Poortmans, P. ; Constantinou, N. ; Weber, D. C. ; Atasoy, B. M. ; Igdem, S. ; Ozsahin, M. ; Ozyar, E. / Treatment results and prognostic factors in primary thyroid lymphoma patients : A Rare Cancer Network study. In: Annals of Oncology. 2011 ; Vol. 22, No. 1. pp. 156-164.
@article{180a2cbd600849189cceeddeef910008,
title = "Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study",
abstract = "Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74{\%} and 71{\%}, respectively, and the disease-free survival (DFS) rates were 68{\%} and 64{\%}. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.",
keywords = "Chemotherapy, Combined modality treatment, Non-Hodgkin's lymphoma, Prognostic factors, Radiotherapy, Thyroid lymphoma",
author = "C. Onal and Li, {Y. X.} and Miller, {R. C.} and P. Poortmans and N. Constantinou and Weber, {D. C.} and Atasoy, {B. M.} and S. Igdem and M. Ozsahin and E. Ozyar",
year = "2011",
doi = "10.1093/annonc/mdq310",
language = "English (US)",
volume = "22",
pages = "156--164",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Treatment results and prognostic factors in primary thyroid lymphoma patients

T2 - A Rare Cancer Network study

AU - Onal, C.

AU - Li, Y. X.

AU - Miller, R. C.

AU - Poortmans, P.

AU - Constantinou, N.

AU - Weber, D. C.

AU - Atasoy, B. M.

AU - Igdem, S.

AU - Ozsahin, M.

AU - Ozyar, E.

PY - 2011

Y1 - 2011

N2 - Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

AB - Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

KW - Chemotherapy

KW - Combined modality treatment

KW - Non-Hodgkin's lymphoma

KW - Prognostic factors

KW - Radiotherapy

KW - Thyroid lymphoma

UR - http://www.scopus.com/inward/record.url?scp=78650394510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650394510&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq310

DO - 10.1093/annonc/mdq310

M3 - Article

C2 - 20587509

AN - SCOPUS:78650394510

VL - 22

SP - 156

EP - 164

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -